A nurse at a provider's office is collecting data from a client who reports taking pseudoephedrine for sinus problems. The nurse should recognize that which of the following conditions from the client's history places the client at risk for harm while taking pseudoephedrine?

Choice A rationale Migraine headaches are characterized by neurovascular changes and cortical spreading depression. While some vasoconstrictors can impact migraine patterns, pseudoephedrine is not specifically contraindicated solely based on a history of migraines. The primary concern with this medication is its systemic sympathomimetic effect. Although patients should monitor for any exacerbation of headache symptoms, the risk profile for a migraine sufferer is significantly lower than the risks posed to a patient with cardiovascular instability or uncontrolled vascular pressure. Choice B rationale Being overweight or having a higher body mass index does not serve as a direct contraindication for the use of pseudoephedrine. While obesity is a risk factor for various metabolic and cardiovascular diseases, the drug itself does not interact with adipose tissue in a way that causes immediate harm. Clinical management for an overweight patient would focus on appropriate dosing based on weight if necessary, but pseudoephedrine does not pose a unique physiological threat tied specifically to weight. Choice C rationale Pseudoephedrine is a sympathomimetic amine that stimulates alpha and beta-adrenergic receptors. This stimulation causes systemic vasoconstriction and increases heart rate, which directly leads to an elevation in blood pressure. For a client with a history of hypertension, taking pseudoephedrine can result in dangerously high blood pressure levels or a hypertensive crisis. Normal blood pressure is typically defined as less than 120 over 80 mmHg. Stimulation of the sympathetic nervous system significantly increases myocardial oxygen demand and peripheral resistance. Choice D rationale Eczema is an inflammatory skin condition and is not affected by the systemic administration of pseudoephedrine. Pseudoephedrine acts primarily on the respiratory mucosa to reduce edema and congestion through vasoconstriction. It does not modulate the immune response or the epidermal barrier integrity involved in atopic dermatitis. Therefore, a history of eczema does not place the client at increased risk for adverse systemic reactions when using this medication for sinus congestion, as the physiological pathways involved are unrelated.